Benitec Biopharma, Inc. (BNTC)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$8.65-1.93%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Benitec Biopharma, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.295
Annual ending 2027-06-30
Revenue	—	21.86M
EPS	—	-1.237
Annual ending 2028-06-30
Revenue	—	17.78M
EPS	—	-1.485

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain disciplined cash management and control operating expenses	Management focuses on cash discipline despite net losses rising to -$11.9M in 2026-Q3.	Broken	cash burn worsens beyond -$5M per quarter	Cash from operations: $-4.939M FY2026-Q4; GAAP. Published target: Quarterly cash from operations better than -$4.5M. Target period is not explicitly aligned with this observation. Source published Sep 14, 2026-4,939,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 1 of the supplied fiscal-period transcripts, as a cash position rather than an explicit cost-control commitment. Total expenses increased from $41.8 million in fiscal 2025 to $51.2 million in fiscal 2026, while cash and cash equivalents were $180.0 million at June 30, 2026. Expense growth alongside the stated cash resources shows limited evidence of expense reduction. Delivery assessment Oct 24, 2026
Advance clinical development of gene-silencing therapies	Benitec advances gene-silencing therapies with a 66% progress score.	Intact	progress score falls below 50%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Strengthen leadership and governance	A supporting condition in Benitec Biopharma, Inc.'s published investment case. The stated target is Maintain stable executive team and governance.	Intact	Major leadership disruption or governance failure	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve net income trend	A supporting condition in Benitec Biopharma, Inc.'s published investment case. The stated target is Net income loss less than -$11.9M per quarter.	Intact	net income loss exceeds -$15M per quarter	Net income: $-12.809M FY2026-Q4; GAAP. Published target: Net income loss less than -$11.9M per quarter. Target period is not explicitly aligned with this observation. Source published Sep 14, 2026-12,809,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 1 of the supplied fiscal-period transcripts, as a cash position rather than an explicit cost-control commitment. Total expenses increased from $41.8 million in fiscal 2025 to $51.2 million in fiscal 2026, while cash and cash equivalents were $180.0 million at June 30, 2026. Expense growth alongside the stated cash resources shows limited evidence of expense reduction. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 2
2026-07-25	Unavailable	Unavailable	1 / 2
2026-07-26	Unavailable	Unavailable	1 / 2
2026-07-27	Unavailable	Unavailable	1 / 2
2026-07-28	Unavailable	Unavailable	1 / 2
2026-07-29	Unavailable	Unavailable	2 / 3
2026-07-30	Unavailable	Unavailable	2 / 3
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	Unavailable	2 / 3
2026-08-03	Unavailable	Unavailable	2 / 3
2026-08-04	Unavailable	Unavailable	2 / 3
2026-08-05	Unavailable	Unavailable	2 / 3
2026-08-06	Unavailable	Unavailable	2 / 3
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	Unavailable	2 / 3
2026-08-09	Unavailable	Unavailable	2 / 3
2026-08-10	Unavailable	Unavailable	2 / 3
2026-08-11	Unavailable	Unavailable	2 / 3
2026-08-12	Unavailable	Unavailable	2 / 3
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	1 / 3
2026-09-16	Unavailable	Unavailable	1 / 3
2026-09-17	Unavailable	Unavailable	1 / 3
2026-09-18	Unavailable	Unavailable	1 / 3
2026-09-19	Unavailable	Unavailable	1 / 3
2026-09-20	Unavailable	Unavailable	1 / 3
2026-09-21	Unavailable	Unavailable	1 / 3
2026-09-22	Unavailable	Unavailable	1 / 3
2026-09-23	Unavailable	Unavailable	1 / 3
2026-09-24	Unavailable	Unavailable	1 / 3
2026-09-25	Unavailable	Unavailable	1 / 3
2026-09-26	Unavailable	Unavailable	1 / 3
2026-09-27	Unavailable	Unavailable	1 / 3
2026-09-28	Unavailable	Unavailable	1 / 3
2026-09-29	Unavailable	Unavailable	1 / 3
2026-09-30	Unavailable	Unavailable	1 / 3
2026-10-01	Unavailable	Unavailable	1 / 3
2026-10-02	Unavailable	Unavailable	1 / 3
2026-10-03	Unavailable	Unavailable	1 / 3
2026-10-04	Unavailable	Unavailable	1 / 3
2026-10-05	Unavailable	Unavailable	1 / 3
2026-10-06	Unavailable	Unavailable	1 / 3
2026-10-07	Unavailable	Unavailable	1 / 3
2026-10-08	Unavailable	Unavailable	1 / 3
2026-10-09	Unavailable	Unavailable	1 / 3
2026-10-10	Unavailable	Unavailable	1 / 3
2026-10-11	Unavailable	Unavailable	1 / 3
2026-10-12	Unavailable	Unavailable	1 / 3
2026-10-13	Unavailable	Unavailable	1 / 3
2026-10-14	Unavailable	Unavailable	1 / 3
2026-10-15	Unavailable	Unavailable	1 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	2 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	7	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 23

$14.00New observation · no comparable prior

$0$7.70$15.40

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain disciplined cash management and control operating expensesPublished status: Broken
Advance clinical development of gene-silencing therapiesDirect metric needs a verified mapping
Strengthen leadership and governanceQualitative condition
Improve net income trendNet income: $-12.809M

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-50.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Benitec Biopharma, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage biotechnology, not an established earnings compounder. The long-term thesis is in a watch state: BB-301 development is progressing, but pivotal-trial design is unresolved and overall financial performance is weak.

What's priced into Benitec Biopharma, Inc.

Valuation evidence is limited to low model confidence, so whether the shares look cheap, fair, or expensive versus peers cannot be assessed from this snapshot. No fragility gates fired, but that does not establish what the market assumes about BB-301 or future results.

What the fundamentals likely do

In the near term, losses and expenses remain substantial: fiscal 2026 operating loss was $51.2 million, and total expenses rose from $41.8 million in fiscal 2025 to $51.2 million in fiscal 2026. BB-301 execution has advanced, with all three Cohort 2 patients treated, but the FDA requested additional data and the pivotal-trial design is still pending; a high-miss-rate industry and recent peer misses add near-term risk.

What Benitec Biopharma, Inc. hinges on

The multi-year thesis hinges on whether BNTC can provide the additional data and settle a pivotal-trial design for BB-301. A guidance cut would be a meaningful negative, while continued strength among sector bellwethers could support the sector backdrop; weakening jobs data could add pressure to cyclical healthcare names.